A Phase 3 interventional study of Matching Placebo and Nintedanib in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 25 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-04-17.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.
Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 3, and was the 3rd registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:
First Affiliated Hospital of Wenzhou Medical University
Ages 40+
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2013.
This study's enrollment of 113 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 49 across the 16 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim: 1 open now, 3 under way, 1 of them phase 3. Of 31 finished, 26 (84%) have results posted.
Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2013, is one of 5 in phase 3, and was the 3rd registered.
Boehringer Ingelheim’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2010.
1 of the studies testing nintedanib in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07583589First Affiliated Hospital of Wenzhou Medical UniversityNintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 36 in Idiopathic Pulmonary Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind clinical trial followed by conversion of each arm to active nintedanib for an additional 6 months comparing the effect of nintedanib 150mg bis in die (BID twice daily) on the progression of IPF measured by using High Resolution Computerized Tomography(HRCT), lung function, functional component (6MWT), biomarkers, and PRO component (PROs) with continued treatment and assessments for up to 18 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Bleeding risk:
Any of the following within 3 months:
Thrombotic risk
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
150 mg twice daily
Drug: Nintedanib
twice daily dosing
Drug: Matching Placebo
twice daily dosing
gelating capsule
Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months
Relative change from baseline in HRCT QLF score at 6 months was calculated as the difference of the QLF score at month 6 minus the QLF score at baseline divided by the baseline QLF score. The QLF score itself ranges from 0 to 100%, where greater values represent a greater amount of lung fibrosis and are considered a worse health status. Hence smaller relative changes from baseline (i.e., ratios) were considered favorable. HCRT assessment obtained during screening visit was considered as baseline.
Time frame: Baseline and 6 Months
Effect of Six Month Delayed Treatment Onset: Relative Change From Baseline in HRCT QLF Score at 12 Months
Relative change from baseline in HRCT QLF score at 12 months was calculated as the ratio of the QLF score at 12 months to baseline. Greater values of the QLF score represented a worse health status and hence smaller relative changes from baseline (i.e., ratios) were considered favorable. HCRT assessment obtained during screening visit was considered as baseline. Note that due to the change in study design, patients randomized to the placebo group were treated with nintedanib after completion of the first 6-month treatment period. Therefore, this new endpoint was defined to address the effect of a 6-month delayed onset of nintedanib treatment.
Time frame: Baseline and 12 Months
Absolute Change in Forced Vital Capacity (FVC) From Baseline at 6 Months
Absolute change in Forced Vital Capacity (FVC) from baseline at 6 months is presented.
Time frame: Baseline and 6 Months
Relative Change in FVC From Baseline at 6 Months
Relative change in FVC from baseline at 6 months is presented.
Time frame: Baseline and 6 Months
Categorical Change in FVC From Baseline at 6 Months
Percentage of participants reporting categorical change in FVC from baseline at 6 months are presented.
Time frame: Baseline and 6 Months
St. George's Respiratory Questionnaire (SGRQ) Total Score Change From Baseline at 6 Months
SGRQ total score change from baseline at 6 months is presented. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6).
Time frame: Baseline and 6 Months
6MWT Total Distance Walked Change From Baseline at 6 Months
Change in total distance covered in 6-minute walk test (6MWT) from baseline at 6 month is presented. The 6-Minutes Walk Test (6-MWT) was conducted according to the American Thoracic Society (ATS) Criteria.
Time frame: Baseline and 6 Months
University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Change From Baseline at 6 Months
University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) change from baseline at 6 months is presented. Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6).
Time frame: Baseline and 6 Months
All-cause Mortality at 6 Months
Percentage of subjects died from all causes between 0 to 6 months are presented.
Time frame: 6 Months
Respiratory Hospitalizations at 6 Months
Percentage of subjects hospitalized due to respiratory problems between 0 to 6 months are presented.
Time frame: 6 Months
Respiratory Mortality at 6 Months
Percentage of subjects who died due to respiratory cause between 0 to 6 months are presented.
Time frame: 6 Months
Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbations at 6 Months
Percentage of subjects experienced first acute IPF exacerbations (based on Investigator reported adverse events) between 0 to 6 months are presented.
Time frame: 6 Months
Patients were randomized to receive nintedanib or placebo in 1:1 ratio. After Global Amendment 1, study design was changed to exploratory, and duration of double blind, placebo-controlled part of study was reduced from 12 months to 6 months, followed by conversion of all patients to open-label nintedanib treatment for a duration of up to 18 months.
| Milestone | Nintedanib | Placebo |
|---|---|---|
| Started | 56 | 57 |
| Completed | 48 | 51 |
| Not completed | 8 | 6 |
| Withdrew: Adverse event | 4 | 5 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Other than specified above | 1 | 0 |
Relative change from baseline in HRCT QLF score at 6 months was calculated as the difference of the QLF score at month 6 minus the QLF score at baseline divided by the baseline QLF score. The QLF score itself ranges from 0 to 100%, where greater values represent a greater amount of lung fibrosis and are considered a worse health status. Hence smaller relative changes from baseline (i.e., ratios) were considered favorable. HCRT assessment obtained during screening visit was considered as baseline.
| percent change | Nintedanib | Placebo |
|---|---|---|
| Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months | 11.407 ± 4.4819 | 14.583 ± 4.3297 |
Relative change from baseline in HRCT QLF score at 12 months was calculated as the ratio of the QLF score at 12 months to baseline. Greater values of the QLF score represented a worse health status and hence smaller relative changes from baseline (i.e., ratios) were considered favorable. HCRT assessment obtained during screening visit was considered as baseline. Note that due to the change in study design, patients randomized to the placebo group were treated with nintedanib after completion of the first 6-month treatment period. Therefore, this new endpoint was defined to address the effect of a 6-month delayed onset of nintedanib treatment.
| percent change | Nintedanib | Placebo |
|---|---|---|
| Effect of Six Month Delayed Treatment Onset: Relative Change From Baseline in HRCT QLF Score at 12 Months | 13.103 ± 4.5454 | 15.622 ± 4.4714 |
Absolute change in Forced Vital Capacity (FVC) from baseline at 6 months is presented.
| milliliter (mL) | Nintedanib | Placebo |
|---|---|---|
| Absolute Change in Forced Vital Capacity (FVC) From Baseline at 6 Months | -14.18 ± 31.050 | -83.18 ± 28.067 |
Relative change in FVC from baseline at 6 months is presented.
| percentage of change | Nintedanib | Placebo |
|---|---|---|
| Relative Change in FVC From Baseline at 6 Months | -0.67 ± 1.05 | -3.02 ± 0.95 |
Percentage of participants reporting categorical change in FVC from baseline at 6 months are presented.
| Percentage of participants | Nintedanib | Placebo |
|---|---|---|
| Decrease >10% or 200 mL | 6.5 | 23.9 |
| Change within ≤10% AND ≤200 mL | 76.1 | 71.7 |
| Increase >10% or 200 mL | 17.4 | 4.3 |
SGRQ total score change from baseline at 6 months is presented. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6).
| Units on a scale | Nintedanib | Placebo |
|---|---|---|
| St. George's Respiratory Questionnaire (SGRQ) Total Score Change From Baseline at 6 Months | -2.24 ± 1.682 | -2.19 ± 1.699 |
Change in total distance covered in 6-minute walk test (6MWT) from baseline at 6 month is presented. The 6-Minutes Walk Test (6-MWT) was conducted according to the American Thoracic Society (ATS) Criteria.
| meters | Nintedanib | Placebo |
|---|---|---|
| 6MWT Total Distance Walked Change From Baseline at 6 Months | 4.93 ± 11.415 | -13.00 ± 11.476 |
University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) change from baseline at 6 months is presented. Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6).
| Units on a scale | Nintedanib | Placebo |
|---|---|---|
| University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Change From Baseline at 6 Months | 3.42 ± 2.156 | -1.46 ± 2.192 |
Percentage of subjects died from all causes between 0 to 6 months are presented.
| Percentage of participants | Nintedanib | Placebo |
|---|---|---|
| All-cause Mortality at 6 Months | 0.0 | 5.3 |
Percentage of subjects hospitalized due to respiratory problems between 0 to 6 months are presented.
| Percentage of participants | Nintedanib | Placebo |
|---|---|---|
| Respiratory Hospitalizations at 6 Months | 0.0 | 7.0 |
Percentage of subjects who died due to respiratory cause between 0 to 6 months are presented.
| Percentage of participants | Nintedanib | Placebo |
|---|---|---|
| Respiratory Mortality at 6 Months | 0.0 | 3.5 |
Percentage of subjects experienced first acute IPF exacerbations (based on Investigator reported adverse events) between 0 to 6 months are presented.
| Percentage of participants | Nintedanib | Placebo |
|---|---|---|
| Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbations at 6 Months | 1.8 | 1.8 |
Collected over From first drug administration till 28 days after end of treatment; up to 19 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib | — | 11/56 (19.6%) | 54/56 (96.4%) |
| Placebo | — | 14/57 (24.6%) | 51/57 (89.5%) |
| Event | Nintedanib | Placebo |
|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 1/56 | 3/57 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/56 | 1/57 |
| PneumoniaInfections and infestations | 0/56 | 2/57 |
| Cardiogenic shockCardiac disorders | 1/56 | 0/57 |
| Myocardial infarctionCardiac disorders | 1/56 | 0/57 |
| Intestinal infarctionGastrointestinal disorders | 1/56 | 0/57 |
| Clostridium difficile infectionInfections and infestations | 1/56 | 0/57 |
| InfluenzaInfections and infestations | 1/56 | 0/57 |
| Lyme diseaseInfections and infestations | 1/56 | 0/57 |
| SepsisInfections and infestations | 1/56 | 0/57 |
| Event | Nintedanib | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 43/56 | 40/57 |
| NauseaGastrointestinal disorders | 16/56 | 20/57 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/56 | 15/57 |
| Weight decreasedInvestigations | 13/56 | 4/57 |
| Decreased appetiteMetabolism and nutrition disorders | 12/56 | 6/57 |
| FatigueGeneral disorders | 11/56 | 9/57 |
| VomitingGastrointestinal disorders | 10/56 | 9/57 |
| NasopharyngitisInfections and infestations | 5/56 | 9/57 |
| HeadacheNervous system disorders | 7/56 | 9/57 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/56 | 9/57 |
Treated Set (TS) consisted of patients who were randomized to a treatment group and received at least 1 dose of study drug.
| Age, Continuous(Years) | Nintedanib | Placebo | Total |
|---|---|---|---|
| Mean | 68.8 ± 7.6 | 66.2 ± 9.4 | 67.5 ± 8.6 |
| Sex: Female, Male(Participants) | Nintedanib | Placebo | Total |
|---|---|---|---|
| Female | 11 | 20 | 31 |
| Male | 45 | 37 | 82 |
Ran from Nov 2013 to primary completion in Oct 2016, 35 months.
Results were first posted in Apr 2018, 1 year 5 months after primary completion. A results delay was requested in Jun 2017.
Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib
Idiopathic Pulmonary Fibrosis →